Richard Lafayette, MD

Richard Lafayette, MD, is a professor of medicine and director of the Glomerular Disease Center at Stanford University Medical Center.

Articles by Richard Lafayette, MD

Kidney Compass: Atacicept and ORIGIN 3 at Kidney Week 2025, with Richard Lafayette, MD

ByBrendon Neuen, MD,Shikha Wadhwani, MD, MS,Richard Lafayette, MD

November 6th 2025

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

HCPLive Five at European Renal Association (ERA) Congress 2025

ByFadi Fakhouri, MD, PhD,Jonathan Barratt, MBChB, PhD, FRCP,Richard Lafayette, MD,Rajiv Agarwal, MD, MS,Brendon Neuen, MD,Shikha Wadhwani, MD, MS,Vlado Perkovic, MBBS, PhD

June 25th 2025

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD

ByRichard Lafayette, MD

June 6th 2025

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

Progress in IgAN and Future Innovations in Nephrology, with Richard Lafayette, MD

ByRichard Lafayette, MD

April 14th 2025

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

ByRichard Lafayette, MD

April 11th 2025

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Latest Updated Articles

HCPLive Five at European Renal Association (ERA) Congress 2025
June 25th 2025

Richard Lafayette, MD

Articles by Richard Lafayette, MD

Kidney Compass: Atacicept and ORIGIN 3 at Kidney Week 2025, with Richard Lafayette, MD

HCPLive Five at European Renal Association (ERA) Congress 2025

Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD

Progress in IgAN and Future Innovations in Nephrology, with Richard Lafayette, MD

Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

Latest Updated Articles

Trending on HCPLive

SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study

Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B

Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial

Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs

What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD